TFF3 facilitates dormancy of anti-estrogen treated ER+ mammary carcinoma.

ABSTRACT:

Background

Tumor dormancy is a substantial clinical obstacle in treatment of estrogen receptor positive mammary carcinoma (ER+MC), contributing to drug resistance, metastatic outgrowth, relapse, and consequent mortality.

Methods

Preclinical models mimicking clinical anti-estrogen-induced ER+MC dormancy were generated in vivo. Function and a mechanism-based combination treatment were determined in the generated dormancy-like models in vitro, ex vivo, and in vivo.

Results

The dormancy models display molecular features of dormancy and tumor mass and cellular dormancy with associated clinical dormancy behavior. Both serum and cancer tissue expression of Trefoil factor 3 (TFF3) are identified as prognostic indicators of dormant ER+MC with TFF3 functioning as an epigenetica

SUBMITTER: Chen S 

PROVIDER: S-EPMC11845601 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature